Life-Science Tools & Sequencing

Kaipu Biotech announced that its wholly owned subsidiary, Chaozhou Kaipu Biochemical Co., Ltd., has obtained a medical device registration certificate issued by the National Medical Products Administration. The approved product is a vaginal microbial nucleic acid detection kit, using PCR-fluorescent probe method, classified as a Class III in vitro diagnostic reagent. The product is used for qualitative detection of Trichomonas vaginalis, Gardnerella vaginalis, and Candida albicans nucleic acids in vaginal secretions.

Danaher announced in early October 2026 that it had launched its first AI-powered autonomous lab at Abcam, combining artificial intelligence, robotics and connected workflows to accelerate the design, building and testing of custom antibodies and other molecular tools. The lab's closed-loop system feeds every experimental result back into its AI models, a setup intended to lift both the speed and scale of reagent discovery while maintaining rigorous validation. The launch reinforces Danaher's Life Sciences automation and AI catalyst but does not materially change near-term sensitivities around bioprocessing demand or the risk that softer respiratory testing and China pricing could leave overall growth below what the market currently embeds. The announcement comes alongside the appointment of Julie Sawyer Montgomery as CEO from 1 October 2026, with execution on connected, automated workflows expected to depend heavily on leadership continuity and capital allocation discipline. Danaher's narrative projects $31.7 billion revenue and $6.1 billion earnings by 2029, requiring 8.1% yearly revenue growth and about a $2.1 billion earnings increase from $4.0 billion today, while three Simply Wall St Community fair value estimates cluster in a tight US$225.66 to US$239.86 range.

Danaher Corporation announced plans to launch its first AI-powered autonomous lab for antibody research, sending its shares up 2% in premarket trading Wednesday. The facility, expected to operate at scale in early 2027, will combine artificial intelligence, robotics and technologies from several Danaher operating companies to help researchers develop custom antibodies and other molecular tools, and is designed to deliver up to 8x faster discovery of affinity reagents and unlock up to a tenfold increase in annual reagent generation. Based at Abcam, a Danaher company, the lab uses AI to create new affinity reagents, including antibodies, then builds and tests each one, feeding results back into the model to improve subsequent designs, bringing together technologies from Beckman Coulter Life Sciences, Cytiva, Genedata, Integrated DNA Technologies, and Molecular Devices in one connected workflow. Julie Sawyer Montgomery, President and Chief Executive Officer of Danaher, said the autonomous lab reflects the kind of progress Danaher is uniquely positioned to deliver, helping turn promising ideas into validated systems faster. The lab represents the first step in a broader Danaher initiative to create smart instruments, integrated workflows and autonomous labs that accelerate scientific research. Ahead of Wednesday's announcement, Barclays analyst Luke Sergott raised the price target on Danaher to $255.00 from $230.00 while maintaining an Overweight rating.

Roche Diagnostics has provided two molecular testing instruments to the Institut National de Santé Publique to support Ebola testing capacity in the Democratic Republic of Congo, where an outbreak caused by Bundibugyo virus has pushed demand for testing beyond current laboratory capacity. Roche will preconfigure the Light cycler and Magna Pure instruments and train local laboratory technicians before deploying the equipment to Bunia for validation testing. The Institut National de Santé Publique will conduct local validation of the Bundibugyo virus, after which Roche anticipates further tests could be shipped and additional instruments deployed. The delivery follows Roche's June announcement that it had developed a Research Use Only molecular PCR test targeting Bundibugyo virus. As of 28 September 2026, UN Health Authority data reported 8,067 confirmed cases and 3,901 deaths, a case fatality rate of 48.4% across 60 health zones in six provinces, and the WHO has assessed the risk in the DRC as very high and confirmed the outbreak remains a public health emergency of international concern.

QIAGEN N.V. announced new artificial intelligence capabilities to help researchers analyze complex biological and genomic data faster while keeping the scientific evidence behind the results visible. The expansion includes IPA Investigator, a new AI research companion for QIAGEN Ingenuity Pathway Analysis, and the new QIAGEN Discovery Platform, which extends these capabilities into automated drug discovery workflows. The new offerings build on more than 25 years of biomedical knowledge from QIAGEN Digital Insights, whose bioinformatics solutions are used by around 150,000 users. The global market for AI in bioinformatics is projected to more than double from about $12 billion in 2026 to more than $25 billion by 2031, according to Mordor Intelligence. At the University of Bergen in Norway, researchers tested IPA Investigator using complex datasets that deliberately introduced misleading sample comparisons, and Dr. Simona Chera, Professor at the University of Bergen, said the tool identified the problem, cautioned against overinterpreting the results and suggested a better experimental design.

NeoGenomics, Inc. issued preliminary third-quarter 2026 revenue guidance of about US$209 million with very strong next-generation sequencing growth and outlined plans to increase its full-year revenue guidance. The company also amended its bylaws to expand its Board to up to eleven directors. In a planned leadership transition, President and COO Warren Stone will become CEO and join the Board in January 2027, while current CEO Tony Zook moves to Executive Chair and the Board refreshes its independent leadership. The stronger revenue outlook, particularly in NGS, supports the near-term revenue catalyst but does not materially change the central risk that high fixed costs and heavy investment could weigh on margins if volumes soften or funding pressures persist. NeoGenomics' narrative projects $997.4 million revenue and $64.1 million earnings by 2029, with a $19.72 fair value estimate.

Bruker Corporation announced a seminal bioRxiv preprint describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution, conducted by principal investigator Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators. By combining intact protein fractionation with diaPASEF mass spectrometry on Bruker timsTOF mass spectrometry systems, the researchers detected 5,077 plasma protein groups across 179,049 distinct proteoforms, with a high-confidence map comprising 44,083 proteoforms and a median of eleven proteoforms per protein. The study indicates that canonical proteins account only for a fraction of protein diversity in the blood stream and may constitute less than half of total protein content, and the workflow did not use nanoparticle-based enrichment. Dr. Markus Ralser, Einstein Professor of Biochemistry and Head of the Institute of Biochemistry at Charité – Universitätsmedizin Berlin, said the first draft of the plasma proteoform atlas shows that proteoforms are not rare exceptions but a defining feature of plasma biology. The preprint, titled "A draft atlas of the human plasma proteome at isoform resolution," was posted on September 28, 2026, and the draft isoform atlas is intended as a starting point for future proteoform in-depth studies across individuals, physiological states and diseases.

Illumina shares jumped 7.7% in the afternoon session after Wall Street analysts raised their price targets on the genomics company, citing expected improvement in clinical sales and new catalysts. Analysts also pointed to growing investor interest in gene-sequencing technology as foundational infrastructure for artificial intelligence applications, according to TipRanks. The stock closed the day at $293.84, up 7.6% from the previous close, and has now gained 119% since the beginning of the year, setting a new 52-week high. The move was notable but not extreme for Illumina, which has seen 17 swings greater than 5% over the past year. The largest of those came 11 months ago, when the stock gained 22.4% after the company reported third-quarter 2025 results that beat profit expectations and raised its full-year guidance.

EpiSign Inc. and Geneyx Genomex Ltd. announced a partnership to advance the integration of genomic and epigenomic analysis for rare-disease interpretation. Under the collaboration, EpiSign METRIC becomes available to Geneyx customers, letting laboratories incorporate epigenomic evidence alongside genomic and phenotypic information in an integrated interpretation workflow. EpiSign METRIC automates analysis of disease-associated DNA methylation episignatures across more than 300 EpiSign-associated conditions, while EpiSign METRIC 5-base extends that capability beyond methylation microarrays to methylation data generated by Illumina 5-base, PacBio HiFi and Oxford Nanopore sequencing. Geneyx Chief Executive Officer David Yizhar said the partnership combines Geneyx's genomic and multi-omics analysis platform with EpiSign's expertise in DNA methylation and episignatures, and EpiSign co-founder and Chief Scientific Officer Dr. Bekim Sadikovic said genome sequencing increasingly generates genetic and epigenetic information from the same assay. EpiSign Chief Executive Officer Dan Sinai said generating genomic and epigenomic information together from a single assay can reduce wet-lab testing and data-generation costs and shorten the diagnostic odyssey for patients and families. EpiSign METRIC 5-base is available for research use only.

CellCarta has established a strategic partnership with Waters Corporation to jointly pursue companion diagnostic and next-generation flow cytometry opportunities with pharmaceutical and biotechnology companies. The collaboration will initially emphasize flow cytometry-based programs, aiming to give sponsors a coordinated path from biomarker strategy through clinical development, regulatory submission and global commercialization. Waters will provide underlying technology capabilities including instrumentation, reagents, standardized panels, assay development, software analysis, and where appropriate custom reagent and IVD commercialization, while CellCarta will integrate and deploy assays across its global CDx Lab Network, supporting Phase I-III clinical trial testing, analytical and clinical evidence generation, regulatory and logistics support, and commercial laboratory services. The companies cited existing platform alignment between CellCarta's CAP-accredited laboratory in Jining, China and BD flow cytometry platforms as a practical foundation for global sponsors seeking to include China in future multinational CDx and biomarker programs. Todd Chermak, President of CellCarta, said the partnership offers sponsors a more connected path from biomarker strategy through global clinical development and, where appropriate, commercialization, and that the companies are already engaging pharmaceutical and biotechnology companies on near-term opportunities.

Analysts lifted their fair value estimate for Tecan Group from CHF 184.10 to CHF 195.73, reflecting updated price targets across recent research. Berenberg sits at the top of the range with a CHF 240 price target and a Buy rating, while Deutsche Bank raised its target in several steps from CHF 138 to CHF 151, then CHF 176, and most recently CHF 198, maintaining a Hold rating. Morgan Stanley moved its target from CHF 142 to CHF 160 and then to CHF 178 while keeping an Equal Weight stance, and Oddo BHF downgraded the stock to Neutral from Outperform with a CHF 192 target. The revised fair value reflects revenue growth assumptions of 5.53%, down from 5.56%, a net profit margin of 9.57% versus 9.70%, a future P/E of 27.00x versus 23.49x, and a discount rate of 4.90% versus 4.82%.

Agilent Technologies Inc. announced the launch of the Agilent BioTek Gen5 AI cell identification module, a new image analysis software add-on that brings AI-based cell identification and segmentation into BioTek Gen5 imaging analysis. Developed for use with compatible Agilent BioTek automated imaging systems, the module performs AI-based segmentation without requiring conventional threshold setting or parameter tuning, and is designed to reduce manual image-analysis steps and support consistent cell counting and confluence analysis. The module supports label-free and fluorescence, live-cell and kinetic assays, and its integration with Gen5 lets researchers using compatible BioTek Cytation and Lionheart automated imagers apply AI-based segmentation within their existing imaging assays. Xavier Amouretti, vice president and BioTek business unit leader at Agilent, said the module brings AI-based segmentation directly into the established BioTek imaging workflow to reduce the effort associated with image analysis. Agilent, which generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide, said the launch expands the image-analysis capabilities available within Gen5 and reflects its focus on integrating automation and AI into laboratory workflows.

Thermo Fisher Scientific Inc. announced on September 23 the launch of the Gibco CHO-K1 Catalog Panel, a cGMP-ready portfolio of basal and feed media designed to accelerate cell growth and protein production for CHO-K1 host lines used in biologics and biosimilars development. Offered in liquid and dry powder formats, the ready-to-use catalog panel lets development teams rapidly evaluate and optimize upstream bioprocesses, and in a 14-day fed-batch study select panel combinations yielded up to 73% higher antibody titer and up to 202% higher peak viable cell density compared to benchmark media. The release follows Thermo Fisher's second-quarter 2026 results, in which revenue grew 10% year-over-year to $11.99 billion on 5% organic growth, GAAP diluted EPS expanded 9% to $4.68, and adjusted EPS rose 13% to $6.03. Second-quarter adjusted operating income reached $2.73 billion, a 22.8% adjusted operating margin with 80 basis points of year-over-year expansion, and the company repurchased $1.0 billion of shares in the quarter while opening its U.S. Bioprocess Design Center in Plainville, Massachusetts. Thermo Fisher's GAAP operating margin stood at 17.4% in the second quarter of 2026, still below its 2021-2022 historic peak levels, and the planned divestiture of its microbiology business introduces a near-term revenue drag that new bioprocess launches must work to replace.

Gilead Sciences and Thermo Fisher Scientific each raised their full-year outlooks after reporting stronger quarterly results, though their growth profiles differ sharply. Gilead's second-quarter product sales excluding Veklury rose 10% to $7.6 billion, with HIV sales up 12% to $5.7 billion, Biktarvy up 7% to $3.8 billion, Descovy up 48% to $967 million, and Yeztugo generating $232 million versus $15 million a year earlier, prompting management to guide 2026 product sales of $30.1 billion to $30.4 billion and product sales excluding Veklury of $29.8 billion to $30.1 billion. Thermo Fisher reported fiscal second-quarter revenue up 10% to $11.99 billion, including 5% organic growth, with adjusted EPS up 13% to $6.03 and adjusted operating margin expanding to 22.8% from 21.9%, and raised its full-year adjusted EPS outlook to $24.93 to $25.33 from $24.64 to $25.12. Gilead's growth carries concentration risk, as HIV accounted for $5.69 billion of its $7.63 billion in quarterly product sales, while $11.2 billion in acquired in-process R&D tied to the Arcellx, Tubulis and Ouro Medicines deals drove GAAP and non-GAAP losses per share of $8.45 and $6.75. Thermo Fisher's broader base depends on a durable recovery in customer spending, with organic growth accelerating from 1% in the first quarter to 5% and China returning to growth even as academic and government demand there remained subdued.

Mission Bio announced that Merck & Co. and Incyte will each present new data generated using its Assay Services and Tapestri Platform at the 16th World Clinical Biomarkers & Companion Diagnostics Summit, alongside a third presentation from Mission Bio itself featuring new clinical data in acute myeloid leukemia. Merck scientist Sydney Hart will present functional genomics findings from a targeted DNA and RNA single-cell assay built with Mission Bio's Assay Services team to study how CRISPR-edited genetic variants affect immune cell function in autoimmune and inflammatory disease, work that links target validation to drug development decision-making. Incyte's Erin Crowgey will present new single-cell clinical data on INCA033989, a monoclonal antibody targeting mutant calreticulin-positive cells in essential thrombocythemia and myelofibrosis, generated with a custom Tapestri assay measuring 46 proteins and 37 genes in the same cell, showing depletion of mutant CALR-positive cells and repopulation by wild-type cells with relevant clinical improvements. Mission Bio Chief Medical Officer Zivjena Vucetic will present clinical study data showing single-cell multiomics achieved 93% sensitivity for measurable residual disease in AML compared to 43% for flow cytometry and 71% for other molecular methods, with additional evidence supporting more accurate stratification of relapse-free survival. The three presentations illustrate how single-cell multiomics connects genetic variation to cellular function, characterizes treatment response in individual cell populations, and identifies residual disease with greater resolution across drug development pipelines.

Agilent Technologies shares have gained about 9.6% in the month since its third-quarter fiscal 2026 earnings report, outperforming the S&P 500. The company reported non-GAAP earnings of $1.62 per share, up 18% year over year and beating the Zacks Consensus Estimate by 9.46%, while revenues of $1.88 billion rose 8.1% on a reported basis and 7.3% on a core basis, surpassing the consensus mark by 2.08%. Strength reflected broad demand across pharma and China, with the Advanced Therapeutics Division growing nearly 30% and instrument book-to-bill above 1.0 for the 10th consecutive quarter. For the fourth quarter of fiscal 2026, Agilent expects revenues of $1.98-$2.00 billion, implying reported growth of 6.4-7.4% and core growth of 5.2-6.2%, with non-GAAP earnings of $1.71-$1.74 per share. For the full fiscal year, revenues are projected at $7.49-$7.51 billion, representing reported growth of 7.8-8.1%, and non-GAAP earnings are expected at $6.18-$6.21 per share, up 15 cents at the midpoint from the prior guide.

The global cell isolation and cell separation market is projected to grow from USD 6.97 billion in 2026 to USD 13.51 billion by 2032, a compound annual growth rate of 11.39%, according to a new report from ResearchAndMarkets.com. The report profiles major players including Thermo Fisher Scientific, Bio-Rad Laboratories, Beckman Coulter, and Sartorius AG. Growth is driven by demand for high-purity, viable cells for single-cell sequencing, flow cytometry, and adoptive cell therapy, with the industry shifting from manual, open protocols toward automated, closed, digitally controlled systems. Artificial intelligence is cited as improving image-based cell recognition, flow cytometry gating, and quality control, while North America leads regional demand and Asia-Pacific expands through biotechnology and genomics investment in China, India, Japan, South Korea, and Australia.

Agilent Technologies executives said the company's growth has accelerated to nearly 10% to 11% from roughly flat two years ago, with operating margin up more than 100 basis points despite tariff headwinds, as they outlined drivers including China, instrument replacement cycles and lab automation at a J.P. Morgan conference. Chief Executive Officer Padraig McDonnell said China delivered broad-based strength in the fiscal third quarter, with double-digit growth in pharma and food and high-teens growth in advanced materials, and management expects the country to be a mid- to high-single-digit long-term growth market. Agilent is less than halfway through its liquid chromatography replacement cycle, which it estimates could add 200 to 300 basis points to the overall business, and about one-quarter through its gas chromatography cycle, worth roughly 100 basis points of growth. The advanced therapeutics CDMO business grew 30% in the fiscal third quarter, and Chief Financial Officer Adam Elinoff said Train C is expected to begin operations in spring 2027 and is 75% booked for next year, with Train C and Train D together roughly doubling site revenue to about $300 million at full capacity. McDonnell said Agilent has begun booking its first reshoring and onshoring orders, with five of the top 10 pharmaceutical companies placing orders, supporting a projected $300 million opportunity by 2030 that represents about one-third of an estimated $1 billion market opportunity.

Twist Bioscience Corporation confirmed on September 16 a strategic partnership with Lilly TuneLab, a platform created by Eli Lilly and Company, under which Twist will provide antibody characterization data services. Twist will also supply data to support AbLab, an antibody developability prediction model, along with high-throughput wet-lab data used to train and improve those models. Through the agreement, TuneLab users will be able to order Twist's antibody services using preferred Twist protocols, generating wet-lab data that can support AI-enabled antibody discovery. The companies did not disclose a minimum purchase commitment, contract value, or specific revenue guidance, and the announcement includes no rights to Lilly drug candidates, milestone payments, or royalties, so the near-term financial impact depends on how much TuneLab users ultimately purchase Twist's services. According to Insider Monkey's database, the number of hedge funds holding Twist rose to 42 in the second quarter from 30 in the first quarter, with Ark Investment Management cutting its position by 29% to $468.1 million, Farallon Capital raising its stake by 50% to $219.79 million, and DE Shaw increasing its position by 2,442% to $121.98 million, while short interest fell to 12.07 million shares as of August 31 from 14.08 million as of July 31 but remained elevated at approximately 18.20%.

Agilent Technologies Inc. announced the launch of the Agilent 4150 TapeStationDx system, the Agilent 4200 TapeStationDx system and Agilent TapeStationDx software, extending its automated electrophoresis portfolio into regulated clinical laboratory environments. The new CE-IVD-labeled systems and software are designed to support standardized and traceable quality control of DNA and RNA samples used in clinical next-generation sequencing workflows, and Agilent said it is among the first providers to offer CE-IVD-labeled automated electrophoresis solutions for clinical NGS sample quality control in the launch regions. The 4150 TapeStationDx system supports lower-throughput laboratories with the flexibility to analyze 1 to 16 samples using tube strips, while the 4200 TapeStationDx system provides scalable throughput from 1 to 96 samples using either tube strips or 96-well plates at a constant cost per sample, with both systems delivering automated sample quality control in approximately 1 to 2 minutes per sample. The accompanying TapeStationDx software controls data acquisition and analysis and includes reporting and data export capabilities, with data integrity features such as audit trails and electronic signatures to help laboratories support compliance with regulations including 21 CFR Part 11 and EU Annex 11. The systems and software are available in the United States, Canada and select European markets including Austria, Belgium, Luxembourg, Switzerland, Germany, Denmark, Spain, Finland, France, the United Kingdom, Ireland, Italy, the Netherlands and Sweden, and Agilent will showcase the portfolio at the Italian Society of Human Genetics National Congress, the American Society of Human Genetics Annual Meeting and the Association for Molecular Pathology Annual Meeting.

Tempus AI is building a research platform based on 100,000 whole genomes linked to long term clinical records, a project that follows its $1.5 billion acquisition of Personalis. The Personalis deal strengthens Tempus' position in molecular residual disease testing, expanding the company from diagnosing and selecting cancer treatments into monitoring patients for cancer recurrence. The new whole genome project arrives after a sharp run in the shares, with a 90 day share price return of 62.68% and a 7 day gain of 31.91%, though the 1 year total shareholder return shows an 11.79% decline. Tempus AI closed at $77.84 against a narrative fair value estimate of $75.68, a level at which 26 investors see the stock as 3% overvalued. The company still carries ongoing losses and meaningful debt, so any setback integrating Personalis could quickly challenge the upbeat narrative.

Charles River Laboratories International unveiled new rapid cell banking and release programs that use advanced sequencing and in vitro tools to shorten biologics and advanced therapy cell bank lead times for biopharma clients. The platform cuts cell bank production time by 40% and combines rapid microbiological methods with NGS characterization, including the iDTECT NGS platform, to support regulatory readiness. Charles River says the approach reduces reliance on animal testing by incorporating alternative in vitro methods aligned with the 3Rs framework. The company, a US life sciences group with a market cap of about $13.1b, positions the offering for time-sensitive programs where delays are costly. Investors will watch for booked projects using the iDTECT NGS platform, client mix in advanced therapies, and whether the services appear in updated segment revenue breakdowns.

IP Group PLC reported that its net asset value exceeded GBP1 billion at the end of H1 2026, with NAV per share rising about 3% to 114p and reaching roughly 117p as of 11 September 2026. The company generated GBP69 million in cash proceeds during the half, up from GBP30 million a year earlier, plus GBP17 million after the period, bringing year-to-date proceeds to about GBP86 million and total proceeds since 2025 to GBP154 million, more than halfway toward its GBP250 million target by the end of 2027. Gross cash stood at GBP239 million at period end, while the portfolio was valued at roughly GBP900 million, or about 103p per share, with the top five assets accounting for about 50p per share. The Pfizer royalty interest rose GBP27 million to just over GBP150 million, and Oxford Nanopore posted GBP117 million in revenue, about 12% growth at constant currency, with gross margin up 400 basis points to 62% and its adjusted EBITDA loss more than halved to just over GBP22 million. Profit for the period was GBP31 million, effectively converted into cash, and about GBP50 million of proceeds is available for shareholder returns under the capital allocation policy.

S&P Dow Jones Indices announced on September 4, 2026, that Bloom Energy and Illumina are joining the S&P 500 benchmark, with the changes taking effect before trading opens on September 21, 2026, replacing Molson Coors, The Trade Desk, and Builders FirstSource. Bloom Energy arrives after product revenue jumped 215% last quarter on hyperscaler demand for onsite fuel-cell capacity, and management raised full-year revenue guidance to $3.9 billion to $4.2 billion. Illumina returns to the index with second-quarter revenue up 9% and raised EPS guidance of $5.30 to $5.40, though management flagged ongoing China and tariff headwinds. The swap barely moves returns for the Vanguard S&P 500 ETF, since new S&P 500 entrants typically begin well under a tenth of a percent of the index, while Vanguard's June 30, 2026 factsheet showed 38% of the fund in its ten largest holdings, including 8% in NVIDIA alone. The composition shift tilts the index toward growth at the margin, with Bloom carrying a beta of 3.81 and a forward P/E of 57x and Illumina at a forward P/E of 34x, while the departing Molson Coors trades at 7x forward earnings with a 4.9% dividend yield and Builders FirstSource at 14x.

Twist Bioscience and Ginkgo Bioworks traded higher on Wednesday after each announced agreements with Lilly TuneLab, a collaborative drug discovery platform established by Eli Lilly. Under its agreement, Twist Bioscience said it will provide antibody characterization data services to TuneLab companies accessing AI and machine learning drug discovery models trained on Lilly-owned research data. CEO Emily Leproust said Twist has the scale and high-throughput capabilities to generate consistent and reliable antibody characterization data these models need to be trained on. Ginkgo Bioworks, through its Ginkgo Datapoints offering, will provide discovery data generation services to TuneLab users. John Androsavich, General Manager at Ginkgo Datapoints, said layering on Ginkgo's ability to quickly generate high-quality, AI-ready datasets at any scale should let TuneLab participants close the loop between digital design and biological reality faster than ever before.

Twist Bioscience Corporation announced an agreement with Lilly TuneLab, the collaborative AI/ML drug discovery platform created by Eli Lilly and Company. Under the deal, Twist will serve as a provider of antibody characterization data services for TuneLab, including for AbLab, an antibody developability prediction model. TuneLab users will be able to order antibody services from Twist using TuneLab preferred Twist protocols to generate high-quality wet lab data, connecting experimental data with AI-enabled discovery. Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, said the company has the scale and high-throughput capabilities to generate the consistent, reliable antibody characterization data these models need to be trained on. Lilly TuneLab is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D.

The global nucleic acid isolation and purification market is projected to grow from USD 5.41 billion in 2026 to USD 10.52 billion by 2035, a compound annual growth rate of 6.9%, according to a new report from ResearchAndMarkets.com. Growth is being driven by demand for molecular diagnostics, next-generation sequencing, personalized medicine, genomics research and advanced drug discovery, with magnetic bead-based purification, automated extraction platforms and microfluidic systems improving processing speed and throughput. Approximately 370 companies currently offer nucleic acid isolation and purification products worldwide, with nearly 45% based in the Asia-Pacific region, and kits account for approximately 65% of the market. North America holds more than 40% of the global market, while the United States alone is expected to account for approximately 30% and expand at a CAGR of 6.8% through 2035. The report profiles key players including Roche, Promega, Macherey-Nagel, Bio-Rad, Danaher, Merck KGaA, Norgen Biotek, Perkin Elmer, Qiagen and Thermo Fisher Scientific.

Mayo Clinic and Thermo Fisher Scientific have launched Precure, LLC, a Mayo Clinic-controlled company that will build one of the world's leading biomedical datasets to identify signs of disease before symptoms appear. Mayo Clinic will serve as majority owner and Thermo Fisher joins as minority owner of the venture, which will generate molecular data from one million biospecimens linked with longitudinal clinical information collected over several years. The effort integrates proteomic, genomic and clinical data, with Thermo Fisher contributing its Olink Explore HT proteomics platform and Thermo Scientific Orbitrap Mass Spectrometry, kits and reagents. Precure, LLC complements Precure Research, Mayo Clinic's investigator-led scientific effort, by providing the scale, infrastructure and collaborations needed to generate population-scale molecular data and translate discoveries into new diagnostics, therapeutics and other healthcare solutions. Mayo Clinic said any financial returns from its involvement would be reinvested in its nonprofit mission of patient care, research and education.

Bangkok Genomics Innovation Public Company Limited, or BKGI, reported total revenue of 386.73 million baht for 2025, an increase of 40.86 million baht, or 11.81%, from the previous year, driven by revenue from sales of laboratory products, which came in at 111.87 million baht, up 37.96%, while service revenue rose 4.34%, amid competition and changes in reimbursement policy for prenatal chromosomal abnormality screening services. Dr. Saowalak Dansakul, Chief Executive Officer of BKGI, said the company aims to drive its Genomics and Precision Medicine business in line with the policy of pushing Thailand toward becoming an international health hub, or Medical Hub, and with the trend toward preventive medicine. The company is preparing for opportunities in the Genomics Thailand Phase 2 project and is laying out a B2B business model in the Wellness and Longevity market to support clinics and partners with genetic testing products and genetic counseling personnel. For the second half of the year, the company expects support from the gradual recognition of revenue from sales of test reagents following delivery of Sequencing, or NGS, machines, as well as steady revenue from the Oncology services group reimbursed through benefits of the National Health Security Office, or NHSO. Meanwhile, data from the National Statistical Office indicates that in 2024 Thailand had 13.68 million people aged 60 and over, up from 11.63 million in 2020, a structural factor supporting the preventive health market.